<DOC>
	<DOCNO>NCT02711813</DOCNO>
	<brief_summary>The purpose study ass whether TAB08 may beneficial compare placebo patient active Systemic Lupus Erythematosus , adequately control current concomitant treatment . Secondary purpose ass efficacy , safety , pharmacokinetic pharmacodynamic parameter study population .</brief_summary>
	<brief_title>TAB08 Patients With Systemic Lupus Erythematosus ( SLE ) , Not Adequately Controlled With Current Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Confirmed diagnosis Lupus Erythematosus accord American College Rheumatology ( ACR ) criterion ( 4 11 ) Active SLE ( SLE Disease Activity Index â‰¥ 6 ) Skin joint SLE manifestation Lupusnephritis and/or central nervous system affection ( neurolupus ) Prohibited treatment Pregnant nursing woman Concomitant systemic therapy dosage modification ( ) within 4 week randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>